Gentel Biosciences, a leader in proteomics discovery tools, announces the availability of the APiX™ Disease Profiling Kit, a robust, cost-effective single-capture antibody array and detection kit suitable for profiling hundreds of disease-related proteins across multiple disease states.

A variety of proteins can be detected representing a broad range of biological functions, including signal transduction, cell-cycle regulation, and apoptosis related to cancer, cardiovascular, neurodegenerative, viral infection, obesity, aging and immunological abnormalities. Differences can be detected in protein abundance between two individual samples from biological fluids, cells, and whole tissue.

The kit combines Gentel’s APiX™ chromogenic detection platform and Clontech’s research-validated Antibody 380 array technology to help scientists study tumor-associated antigens, compare proteomic and transcriptomic data, and perform target identification and validation using an alternate readout to current fluorescent offerings. In line with Gentel’s unique approach to bring proteomics to all biological researchers, the kit measures data using the Gentel Proteomics Multi-System™ and AthenaQuant® analysis suite of software. The all-inclusive, “scan to analysis” workflow empowers both experts and novices with the necessary tools to conduct an experiment and obtain meaningful proteomics data in about one day.

“This launch expands the application of our APiX™ chromogenic detection technology to include proven high density antibody arrays”, said Alex Vodenlich, Gentel’s President and CEO. “The benefits here are clear; researchers can now discover and profile disease states at the protein level without the requirement of special training or expensive fluorescent or bead-based systems. We’re bridging the technology gap between genomics and proteomics research by helping scientists with little or no expertise in proteomics perform high throughput analysis of proteomic profiles at a fraction of cost and time involved with existing platforms”, he continued. “Our aim is to not only to improve the existing proteomics research workflow but get more scientists involved in multiplex protein analysis and biomarker discovery. Our objective remains the same: Make proteomics research easy and cost effective so everyone can do it. We want to be at the forefront of enabling discovery research and high throughput validation of biomarkers.”

The kit will be the first in a series of high-value products and services Gentel intends to launch in the the second half of 2010. As an introduction to the technology, Gentel will provide scanning and data reporting for new customers’ inaugural kit purchase. To learn more about the APiX™ Disease Profiling Kit, see how it augments your proteomics-research workflow and find out how to take advantage of the free “scan and report” service offer, please visit www.gentelbio.com/products/protein-array-kits/apix-disease-profiling-kit.html.

About Gentel Biosciences, Inc.

Gentel’s mission is to deliver cost-effective, easy-to-use and reliable proteomics products and services that enable researchers to perform faster discovery, validation and screening of protein biomarkers. Gentel’s headquarters is located in Madison, Wisconsin.